Sodium glycerophosphate

Name: Sodium glycerophosphate
SKU: ACM154804510
Rating: 5 (1 reviews)

CAS

154804-51-0

Catalog Number

ACM154804510

Category

Main Products

Molecular Weight

216.04

Molecular Formula

C3H7Na2O6P

If you have any other questions or need other size, please get a quote.

Specification

Synonyms

disodium;1,3-dihydroxypropan-2-yl phosphate;hydrate

Appearance

White Powder

Preparation of Chitosan/Sodium β-Glycerophosphate Thermosensitive Hydrogel

Deng, Aipeng, et al. Materials Science and Engineering: C, 2017, 78, 1147-1154.

This work used sodium β-glycerophosphate (β-GP) and sodium bicarbonate (NaHCO3) as gelling agents to make high-performance chitosan hydrogels with rapid gelation. NaHCO3 and β-GP combined to produce a combinatorial effect, and the hydrogel made with 150 μl of 50% β-GP in 0.4 M NaHCO3 accelerated the gelation time, enhanced heat stability and mechanical strength with minimizing cytotoxic.
Preparation of hydrogel
· Chitosan powder was sterilized overnight using ultraviolet light and then dispersed in deionized water. Following this, hydrochloric acid (final concentration 0.1 M) was added while stirring. The solution was allowed to sit at room temperature overnight to ensure complete dissolution of chitosan, after which it was stored at 4 °C.
· The β-GP was half-diluted in NaHCO3 at 0.1 M to 0.4 M and sterilized by 0.22 m filter at 4 °C. Then added the gel agents gradually under magnetic stirring to obtain a consistent mixture with chitosan remaining at 2% (w/v). The pH of the pre-gelling solutions was taken on a pH meter. The solutions were then gelled at 37 °C.

Application of Sodium Glycerophosphate in Parenteral Nutrition Solution

Wang, Hsueh-Ju, et al. Pediatrics & Neonatology, 2020, 61(3), 331-337.

This work evaluated the solubility of sodium glycerophosphate (NaGP) and calcium gluconate in neonatal parenteral nutrition (PN) solution and found that the two have very good compatibility. The use of NaGP in neonatal PN can prevent calcium and phosphorus precipitation, thereby increasing the calcium and phosphorus supply of premature infants.
· Evaluation method
The PN solutions contained calcium gluconate at 50 mEq/L and sodium glycerophosphate (NaGP) at 25 mmol/L, along with either 1% or 4% amino acids and 10% or 20% dextrose. A PN solution with potassium phosphate was also assessed for comparison. The evaluation methods included visual inspection, light obscuration particle count testing, and pH measurement. The solutions were tested immediately after compounding, after 24 hours of storage at 25 °C, and after being kept at 2°C-8°C for 2 or 9 days, followed by another 24 hours at 25 °C.
· Experimental results
There was no visual deposition in the PN solutions with NaGP, regardless of concentration or storage conditions. These solutions met the compatibility criteria, showing fewer than 25 particles/mL measuring ≥10 μm in diameter and fewer than 3 particles/mL measuring ≥25 μm in diameter. In contrast, visual deposition was clearly observed in the PN solution that contained potassium phosphate immediately after formulation.